HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a $19 price target.
May 13, 2024 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Cogent Biosciences with a $19 price target, indicating strong analyst confidence in the company's future performance.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. Maintaining a Buy rating along with a substantial price target suggests a bullish outlook for Cogent Biosciences, which could lead to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100